Constantino Michael T.

Director Constantino Michael T. purchased 16,000 shares of HUMA at $1.26 on 2025-04-07, doubling holdings to 32,950 shares amid steep 90-day decline.

Constantino Michael T. purchased 16,000 shares at $1.26, increasing his holdings by 94.4% to 32,950 shares in a financially distressed company: Humacyte reported $241,000 in quarterly revenue, a $-39.2M net loss, and a negative full-year result, with a market cap of $178.4M. The stock has declined 87.8% from its 52-week high and 75.4% over the past 90 days, falling -62.8% in the 30 days preceding this transaction. His prior three purchases at HUMA show mixed outcomes: one achieved -27.1% at 90 days, another -15.1%, and one +0.2%, with only 1 of 3 prior buys well-timed at the 90-day mark. Across his cross-ticker track record, his 3 prior buys averaged -14.0% 90-day returns with a 33.33% win rate, suggesting limited predictive timing ability. A cluster of 2 other insiders also bought within 14 days, though this may reflect regulatory requirement disclosures rather than coordinated conviction. The purchase at a depressed valuation in a loss-making business warrants scrutiny of whether this reflects material non-public information or routine portfolio activity.

Director Constantino Michael T. buys 4,600 shares of HUMA at $4.39, raising stake 37.2% to 16,950 shares amid -19.2% 90-day decline.

Director Constantino Michael T. purchased 4,600 shares of Humacyte at $4.39 on 2024-12-04, increasing his holdings by 37.2% to 16,950 shares. This follows a steep 90-day decline of -19.2% for the stock and a 52-week setback of -53.2% from the high of $9.46. His cross-ticker track record shows a 50.00% 90-day win rate with an average 90-day return of -7.4% across prior buys, while at HUMA specifically, his 1 prior measurable buy (2023-05-18) yielded +0.2% over 90 days—a narrow win, though his more recent buy on 2024-08-15 at this ticker declined -15.1% over 90 days. The company remains unprofitable with a net loss of $-39.2M in its latest full fiscal year and quarterly revenue of only $241.0K, providing limited fundamental support for the purchase at current valuations.

Director Constantino buys 3,100 HUMA shares at $6.29; stock -35.1% from 52-week high amid unprofitable operations.

Director Michael T. Constantino purchased 3,100 shares at $6.29, increasing his holdings by 33.5% to 12,350 shares. The transaction occurred as HUMA trades -35.1% from its 52-week high of $9.46 and has declined 30.2% over the prior 30 days. Humacyte remains unprofitable with $-56.7M net income in the most recent fiscal year against quarterly revenue of $241.0K, signaling significant cash burn relative to revenue scale. While Constantino's prior buy at HUMA in May 2023 delivered a positive 90-day return of +0.2%, the company's current financial trajectory and the stock's sharp recent weakness present a materially different context than the earlier purchase.